Shopping Cart
- Remove All
- Your shopping cart is currently empty
NPT200-11 is an orally bioavailable and brain penetrating inhibitor of accumulation of alpha-synuclein (ASYN) misfolding and aggregation. NPT200-11 can be used in studies about the underlying pathology of synucleinopathies including Parkinson's disease (PD), dementia with Lewy bodies (DLB) and Multiple Systems Atrophy (MSA).
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | 185 € | Backorder | |
5 mg | 415 € | Backorder | |
10 mg | 622 € | Backorder | |
25 mg | 1.119 € | Backorder | |
50 mg | 1.679 € | Backorder | |
100 mg | 2.519 € | Backorder | |
200 mg | 3.779 € | Backorder |
Description | NPT200-11 is an orally bioavailable and brain penetrating inhibitor of accumulation of alpha-synuclein (ASYN) misfolding and aggregation. NPT200-11 can be used in studies about the underlying pathology of synucleinopathies including Parkinson's disease (PD), dementia with Lewy bodies (DLB) and Multiple Systems Atrophy (MSA). |
In vivo | In the Line 61 transgenic mouse model overexpressing human wild type ASYN, NPT200-11 (5 mg/kg; i.p.) results in a time-dependent and progressive reduction in retinal ASYN pathology. NPT200-11 reduced alpha-synuclein pathology in cortex, reduced associated neuroinflammation (astrogliosis), normalized striatal levels of the dopamine transporter (DAT) and improved motor function[1]. |
Cas No. | 2227057-23-8 |
Relative Density. | no data available |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO: Soluble |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.